




RealRate

PHARMACEUTICAL 2022

Aravive Inc
Rank 301 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aravive Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Aravive Inc is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 35% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	62,745	Assets	67,787
Cost of Goods Sold	0	Liabilities	25,565
Intangible Assets	0	Expenses	48,091
Liabilities, Current	17,941	Revenues	7,442
Liabilities, Non-Current	7,624	Stockholders Equity	42,222
Other Assets	4,642	Net Income	-39,151
Other Compr. Net Income	0	Comprehensive Net Income	-39,151
Other Expenses	0	BaseVar	75,192
Other Liabilities	0	ECR before LimitedLiability	113%
Other Net Income	1,498	Economic Capital Ratio	241%
Other Revenues	7,442		
Property and Equipment	400		
Research and Development	37,541		
Selling, General and Administrative Expense	10,550		